Stuart A. Weinzimer, United States of America
Yale University PediatricsModerator of 1 Session
Presenter of 2 Presentations
Human factor in closed-loop
Abstract
Background and Aims / Part 1
Type 1 diabetes mellitus is a chronic condition with a high degree of self-management burden that can significantly negatively impact quality of life. Advances in diabetes technology have led to improvements in overall metabolic control but have been less successful at decreasing user and caregiver burden. Advanced diabetes devices and integrated automated systems hold the promise to finally simultaneously improve glycemic control and quality of life. Successful adoption of these devices, however, requires not only that they can improve glycemic control, but that they can also be introduced and incorporated into daily living. Such human factors issues as comfort, wearability, trust, and ease of use are as important as accuracy and precision. In this presentation we will discuss how human factors issues have shaped the evolution of advanced diabetes devices and highlight features important to potential users of these devices.
The role of subcutaneous glucagon
Abstract
Background and Aims / Part 1
Type 1 diabetes mellitus is characterized not only by insulin deficiency, but also dysregulation of endogenous glucagon secretion. Impaired glucagon response to hypoglycemia renders the person with diabetes prone to severe hypoglycemia and represents one of the major impediments to achieving optimal glycemic control and quality of life. Due to instability of recombinant glucagon in liquid form, until now the only roles of subcutaneous glucagon in the treatment of type 1 diabetes have been as rescue for severe hypoglycemia, and less commonly, mini-doses for prevention of hypoglycemia during acute illness or exercise. The recent availability of liquid-stable glucagon has enabled the development of improved methods to treat and/or prevent hypoglycemia, as well as raised the possibility of feasible dual-hormone artificial pancreas systems. This presentation will highlight key studies demonstrating the importance of glucagon in successful management of type 1 diabetes, both as a standalone drug and as part of a dual-hormone system.